How does Moderna cancer vaccine work? On October 22, 2026, Moderna and Merck shared detailed Phase 3 data that put fresh numbers behind the answer. The personalized therapy, called intismeran autogene, cut the risk of melanoma returning or causing death by 42% when doctors added it to Keytruda. Full results debut on Saturday, October 24, 2026, at the European Society for Medical Oncology (ESMO) Congress.
The data also earned acceptance for publication in The New England Journal of Medicine. Here is what the treatment is, how it works, and what the newest trial results show.
What Is the Moderna Cancer Vaccine?
The experimental treatment goes by the name intismeran autogene. Earlier names included mRNA-4157 and V940. Moderna and Merck, which operates as MSD outside the United States and Canada, develop it together.
No regulator has approved it yet. Patients can only receive it through clinical trials right now.
The word “vaccine” can mislead people. Unlike shots for measles or HPV, this treatment does not prevent cancer in healthy people. It targets patients who already had a tumor removed and want to lower the odds of relapse. Scientists call it an individualized neoantigen therapy.
How Does Moderna Cancer Vaccine Work Inside the Body?
The process starts with the patient’s own tumor. Each dose is built from scratch for one person, which makes it very different from a standard vaccine. Here is the sequence:
- Surgery and sampling. Surgeons remove the melanoma. Labs then sequence the tumor’s DNA and compare it with the patient’s normal DNA.
- Finding neoantigens. Cancer cells carry mutations that create abnormal proteins. These proteins, called neoantigens, appear on tumor cells but not on healthy ones. A computer algorithm predicts which neoantigens are most likely to wake up the immune system.
- Building the blueprint. The team uses those picks to design a custom treatment. Each therapy contains one synthetic mRNA that codes for up to 34 neoantigens.
- Injection. Patients receive the treatment by injection. In the Phase 3 trial, the dose was 1 mg every three weeks, for up to nine doses.
- Training the immune system. Cells in the body read the mRNA and make the neoantigen proteins. They then show those proteins to the immune system, which builds T-cell responses aimed at cancer cells carrying the same markers.
The mRNA cannot cause cancer. It codes only for small, nonfunctional pieces of tumor proteins, not whole working ones.
The approach also explains why the therapy cannot work as a preventive shot. No tumor exists yet in a healthy person, so there is nothing to sequence. The blueprint needs a real tumor to read.
Why Keytruda Joins the Treatment
Intismeran does not work alone in the trials. Doctors pair it with Keytruda (pembrolizumab), Merck’s anti-PD-1 immunotherapy.
Cancer cells often use the PD-1 pathway as a brake on T cells. Keytruda blocks that interaction and frees T cells to act. The two drugs split the job. The mRNA therapy teaches T cells what to hunt, and Keytruda lets them keep hunting.
In the Phase 3 trial, patients received Keytruda at 400 mg every six weeks for up to nine cycles, which covers about one year. The comparison group received a placebo plus the same Keytruda schedule.
Phase 3 INTerpath-001 Results
Moderna and Merck first announced that the trial met its goals on August 19, 2026. The October 22 release added the numbers. INTerpath-001 enrolled 1,137 patients with completely resected stage IIB to IV melanoma. Researchers randomized them 2:1 to the combination or to Keytruda alone.
After a median follow-up of 24.6 months, the combination beat Keytruda alone on both main measures:
| Measure | Result |
|---|---|
| Risk of recurrence or death (RFS) | 42% lower (HR 0.58; 95% CI, 0.45–0.75; p<0.001) |
| Risk of distant metastasis or death (DMFS) | 38% lower (HR 0.62; 95% CI, 0.45–0.85; p=0.002) |
| Two-year RFS rate | 82.2% with combination vs. 70.0% with Keytruda alone |
| Two-year DMFS rate | 88.5% with combination vs. 80.2% with Keytruda alone |
The timing of the benefit stands out. During the first six months, while patients received their immunization doses, the combination performed about the same as Keytruda alone. After six months, the picture changed. A pre-specified analysis showed a 58% lower risk of recurrence or death (HR 0.42) and a 50% lower risk of distant metastasis or death (HR 0.50).
A separate analysis excluded patients who missed their planned doses. In that group, the combination lowered the risk of recurrence or death by 49% and the risk of distant metastasis or death by 45%.
Overall survival data have not matured. The companies report a favorable trend, and the study continues to track it. The benefits appeared generally consistent across pre-specified patient subgroups.
Earlier Phase 2b Data Set the Stage
Phase 3 builds on the KEYNOTE-942 study. At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, the companies presented five-year follow-up from that Phase 2b trial in high-risk stage III and IV melanoma.
The combination reduced the risk of recurrence or death by 49% (HR 0.51) and the risk of distant metastasis or death by 59%. Median follow-up reached 60.3 months. An exploratory analysis also showed an encouraging trend in overall survival, though the sample was small and the result was not conclusive.
Safety and Side Effects
The safety profile matched earlier studies of the combination, and the companies reported no new safety signals. Most side effects resembled common vaccine reactions.
- Treatment-related adverse events: 95.8% in the combination arm vs. 90.0% with Keytruda alone
- Grade 3 to 5 events: 14.2% vs. 13.4%
- Most common problems: fever (52.2%), injection site pain (51.0%), and fatigue (38.5%)
Keytruda carries its own risks, including immune-related reactions that can affect organs such as the lungs, intestines, liver, and thyroid. Patients should talk with their oncologist about those risks.
The trial also tracked deaths. Eight deaths occurred in the treatment arm. Five happened before those patients received intismeran, and the other three did not link to the therapy. Anyone weighing treatment options should review the full data with a cancer specialist.
Who Could Benefit?
The trial studied adults with completely resected, high-risk cutaneous melanoma at stages IIB through IV. That is the group where relapse worries remain high even after successful surgery.
Melanoma remains a major concern for American readers. An estimated 112,000 new melanoma cases and more than 8,500 deaths are expected in the United States in 2026. Recurrence most often happens within the first two years after surgery, and more than half of patients who relapse develop distant metastases in organs such as the lung, liver, or brain.
The results apply only to this patient group. They do not show that the therapy will work against other cancers.
What Happens Next for the Moderna Cancer Vaccine?
Moderna and Merck say they are engaging with regulatory authorities based on the Phase 3 data. As of today, October 23, 2026, no approval has been granted, and the companies have not announced a decision date. Patients cannot get the treatment outside a trial.
The data reached the public a little earlier than planned. Results appeared on a medical news site before the scheduled presentation, and the companies and ESMO released the data ahead of schedule.
The research program continues to grow. Merck and Moderna now run nine Phase 2 and Phase 3 trials across several tumor types, including three Phase 3 studies in non-small cell lung cancer. Other studies look at bladder cancer, kidney cancer, and, in an early Phase 1 trial, pancreatic cancer.
Analysts have urged caution about extending the melanoma success to other cancers. Melanoma tends to respond well to immune-based treatment, so lung and other tumors may need more data first.
Why Melanoma Came First
Melanoma carries a high number of mutations, because ultraviolet light damages skin cells over time. More mutations mean more neoantigens, and more neoantigens give the immune system more targets to learn.
Doctors also know that immunotherapy works well in this cancer. Keytruda has treated melanoma for years. The period after surgery offers a clean test, because researchers can track whether cancer returns and compare two groups over time.
Merck and Moderna started the Phase 3 study in July 2023. The companies describe the October 2026 result as the first positive Phase 3 readout for an individualized neoantigen therapy and for an mRNA-based cancer treatment. Scientists will now look for the same signal in other tumor types.
The Bottom Line
The Moderna cancer vaccine reads the genetic fingerprint of one patient’s tumor, then trains the immune system to hunt cells that carry it. Paired with Keytruda, that approach beat Keytruda alone in a large Phase 3 trial. The treatment is not approved, and survival data are still maturing, but the October 22 results mark a significant step for personalized mRNA medicine.
What do you think about personalized cancer vaccines? Share your thoughts in the comments and check back for the latest updates as new trial data arrive.